- Home
- USIO vs RPTX Comparison
USIO vs RPTX Comparison
Compare USIO & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- RPTX
- Stock Information
- Founded
- USIO 1998
- RPTX 2016
- Country
- USIO United States
- RPTX Canada
- Employees
- USIO N/A
- RPTX N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- RPTX Health Care
- Exchange
- USIO Nasdaq
- RPTX Nasdaq
- Market Cap
- USIO 36.6M
- RPTX 38.3M
- IPO Year
- USIO N/A
- RPTX 2020
- Fundamental
- Price
- USIO $1.56
- RPTX $1.36
- Analyst Decision
- USIO Strong Buy
- RPTX Strong Buy
- Analyst Count
- USIO 2
- RPTX 3
- Target Price
- USIO $5.00
- RPTX $4.50
- AVG Volume (30 Days)
- USIO 50.2K
- RPTX 502.5K
- Earning Date
- USIO 05-14-2025
- RPTX 05-20-2025
- Dividend Yield
- USIO N/A
- RPTX N/A
- EPS Growth
- USIO N/A
- RPTX N/A
- EPS
- USIO 0.12
- RPTX N/A
- Revenue
- USIO $82,931,840.00
- RPTX $53,477,000.00
- Revenue This Year
- USIO $16.14
- RPTX N/A
- Revenue Next Year
- USIO $13.51
- RPTX $7.14
- P/E Ratio
- USIO $13.17
- RPTX N/A
- Revenue Growth
- USIO N/A
- RPTX 4.58
- 52 Week Low
- USIO $1.24
- RPTX $0.89
- 52 Week High
- USIO $2.92
- RPTX $4.29
- Technical
- Relative Strength Index (RSI)
- USIO 51.96
- RPTX 59.23
- Support Level
- USIO $1.56
- RPTX $1.31
- Resistance Level
- USIO $1.68
- RPTX $1.48
- Average True Range (ATR)
- USIO 0.09
- RPTX 0.10
- MACD
- USIO -0.01
- RPTX 0.00
- Stochastic Oscillator
- USIO 47.83
- RPTX 57.14
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.